|
1
|
Remschmidt C, Fesenfeld M, Kaufmann AM and
Deleré Y: Sexual behavior and factors associated with young age at
first intercourse and HPVvaccine uptake among young women in
Germany: Implications for HPV vaccination policies. BMC Public
Health. 14(1248)2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ghosh I, Mittal S, Banerjee D, Singh P,
Dasgupta S, Chatterjee S, Biswas J, Panda C and Basu P: Study of
accuracy of colposcopy in VIA and HPV detection-based cervical
cancer screening program. Aust N Z J Obstet Gynaecol. 54:570–575.
2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Muñoz N, Kjaer SK, Sigurdsson K, Iversen
OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA,
Tay EH, et al: Impact of human papillomavirus (HPV)-6/11/16/18
vaccine on all HPV-associated genital diseases in young women. J
Natl Cancer Inst. 102:325–339. 2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
McKee CH, Onder Z, Ashok A, Cardoso R and
Moroianu J: Characterization of the transport signals that mediate
the nucleocytoplasmic traffic of low risk HPV11 E7. Virology.
443:113–122. 2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Stern PL, van der Burg SH, Hampson IN,
Broker TR, Fiander A, Lacey CJ, Kitchener HC and Einstein MH:
Therapy of human papillomavirus-related disease. Vaccine. 30 (Suppl
5):F71–F82. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gootenberg JS, Abudayyeh OO, Lee JW,
Essletzbichler P, Dy AJ, Joung J, Verdine V, Donghia N, Daringer
NM, Freije CA, et al: Nucleic acid detection with
CRISPR-Cas13a/C2c2. Science. 356:438–442. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Abudayyeh OO, Gootenberg JS,
Essletzbichler P, Han S, Joung J, Belanto JJ, Verdine V, Cox DBT,
Kellner MJ, Regev A, et al: RNA targeting with CRISPR-Cas13.
Nature. 550:280–284. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zhen S, Hua L, Takahashi Y, Narita S, Liu
YH and Li Y: In vitro and in vivo growth suppression of human
papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9.
Biochem Biophys Res Commun. 450:1422–1426. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kennedy EM, Kornepati AV, Goldstein M,
Bogerd HP, Poling BC, Whisnant AW, Kastan MB and Cullen BR:
Inactivation of the human papillomavirus E6 or E7 gene in cervical
carcinoma cells by using a bacterial CRISPR/Cas RNA-guided
endonuclease. J Virol. 88:11965–11972. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Paner GP, Stadler WM, Hansel DE, Montironi
R, Lin DW and Amin MB: Updates in the eighth edition of the
tumor-node-metastasis staging classification for urologic cancers.
Eur Urol. 73:560–569. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bharti AC, Singh T, Bhat A, Pande D and
Jadli M: Therapeutic strategies for human papillomavirus infection
and associated cancers. Front Biosci (Elite Ed). 10:15–73.
2018.PubMed/NCBI View
Article : Google Scholar
|
|
12
|
Liu DZ, Jin YX, Hou H, Huang YZ, Yang GC
and Xu Q: Preparation and identification of activity of
anti-HPV-6b/11E1 universal ribozyme-Rz1198 in vitro. Asian J
Androl. 1:195–201. 1999.PubMed/NCBI
|
|
13
|
Chen XZ, Zhu KJ, Xu Y, Tang XY, Cai XZ,
Zhang X and Cheng H: RNA interference silences the human
papillomavirus 6b/11 early gene E7 in vitro and in vivo. Clin Exp
Dermatol. 35:509–515. 2010.PubMed/NCBI View Article : Google Scholar
|
|
14
|
De Buhr H and Lebbink RJ: Harnessing
CRISPR to combat human viral infections. Curr Opin Immunol.
54:123–129. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hsu DS, Kornepati AVR, Glover W, Kennedy
EM and Cullen BR: Targeting HPV16 DNA using CRISPR/Cas inhibits
anal cancer growth in vivo. Future Virol. 13:475–482.
2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhu D, Shen H, Tan S, Hu Z, Wang L, Yu L,
Tian X, Ding W, Ren C, Gao C, et al: Nanoparticles based on poly
(β-Amino Ester) and HPV16-targeting CRISPR/shRNA as potential drugs
for HPV16-related cervical malignancy. Mol Ther. 26:2443–2455.
2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yoshiba T, Saga Y, Urabe M, Uchibori R,
Matsubara S, Fujiwara H and Mizukami H: CRISPR/Cas9-mediated
cervical cancer treatment targeting human papillomavirus E6. Oncol
Lett. 17:2197–2206. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Liu Y, Cai Z and Zhang X: Reprogrammed
CRISPR-Cas9 targeting the conserved regions of HPV6/11 E7 genes
inhibits proliferation and induces apoptosis in E7-transformed
keratinocytes. Asian J Androl. 18:475–479. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hu Z, Yu L, Zhu D, Ding W, Wang X, Zhang
C, Wang L, Jiang X, Shen H, He D, et al: Disruption of HPV16-E7 by
CRISPR/Cas system induces apoptosis and growth inhibition in HPV16
positive human cervical cancer cells. Biomed Res Int.
2014(612823)2014.PubMed/NCBI View Article : Google Scholar
|
